Canaccord Genuity Maintains Buy on Beam Therapeutics, Raises Price Target to $79
Canaccord Genuity analyst Whitney Ijem maintains Beam Therapeutics (NASDAQ:BEAM) with a Buy and raises the price target from $78 to $79.
Share
Why It Matters
An expert who studies stocks thinks Beam is worth about $79 per share. When analysts raise their price targets, it means they see reasons to stay hopeful about the company's future.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.